RVTYRevvity, Inc.

Ticker: RVTY | Price: $169.54 | Today's Change: +11.76%

---

What Happened

Revvity, Inc. filed an 8-K with the SEC on 2026-11-03, disclosing its financial results for the second quarter of fiscal year 2026 under Item 2.02 (Results of Operations and Financial Condition). Revenue for Q2 FY2026 came in at $1.385 billion, operating income reached $163.0 million, and net income was $42.2 million. Basic and diluted earnings per share were both $0.81 for the quarter. The market's reaction was sharply positive, with shares rallying 11.76% on the day.

---

Why It Matters

The scale of today's share price move — north of 11% — signals that the market viewed these results as a meaningful positive surprise relative to prevailing expectations. A quarterly revenue run-rate of $1.39 billion represents a substantial business, and operating income of $163 million translates to an operating margin of roughly 11.8% for the quarter. Net income of $42.2 million, while more modest relative to operating income, reflects the impact of below-the-line items such as interest and taxes. For investors watching Revvity's ongoing transformation as a focused life sciences and diagnostics company, the Q2 figures provide a concrete data point on the revenue trajectory and profitability at the operating level.

---

Analysis

The immediate price reaction of nearly 12% is the clearest signal that this quarter's results exceeded what the market had priced in. This follows StockWatch's initiating coverage of Revvity (published 2026-09-15), and today's earnings-driven gap significantly alters the near-term trading context that existed at the time of that initiation. Several dynamics are worth monitoring going forward:

• Revenue trajectory: A single-quarter revenue figure of $1.385 billion annualizes to a substantial run rate; the key question is whether this pace can be sustained or improved upon in the second half of FY2026.
• Operating leverage: With operating income at ~$163 million on ~$1.385 billion in revenue, the company is generating meaningful operating leverage — but the gap between operating income and net income ($42.2M) warrants scrutiny of interest expense and other non-operating items.
• EPS quality: Basic and diluted EPS being identical at $0.81 suggests minimal dilution from options or convertibles, which is generally a positive signal on capital structure discipline.
• Guidance: Investors will be focused on whether management accompanied these results with updated full-year guidance — any forward commentary in the earnings materials would be a critical input for reassessing the company's trajectory.

The comparison XBRL data point from FY2022 ($1.028 billion in annual revenues) provides a useful long-term context: if Q2 FY2026 alone generated $1.385 billion, the company's revenue scale has grown dramatically from that prior-year base, underscoring the strategic reshaping Revvity has undergone since its rebranding from PerkinElmer.

---

Disclaimer

This report is a news and informational summary based solely on data contained in the referenced SEC filing. It does not constitute investment advice, and no Buy, Hold, or Sell rating or price target is expressed or implied herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Existing Coverage

StockWatch has full coverage on RVTY, published 2026-09-15. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-03. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/31791/000003179126000031/pki-20261103.htm